NASDAQ:ALIM Alimera Sciences (ALIM) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free ALIM Stock Alerts $3.65 +0.17 (+4.89%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$3.43▼$3.7850-Day Range$3.31▼$4.2152-Week Range$1.56▼$4.38Volume143,580 shsAverage Volume32,297 shsMarket Capitalization$191.19 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Alimera Sciences alerts: Email Address Alimera Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside105.5% Upside$7.50 Price TargetShort InterestHealthy0.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.32 out of 5 starsMedical Sector3001st out of 5,424 stocksPharmaceutical Preparations Industry1345th out of 2,550 stocks 3.5 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlimera Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.21% of the outstanding shares of Alimera Sciences have been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently increased by 3.22%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 1.7 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Alimera Sciences this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ALIM on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.40% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.83% of the stock of Alimera Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlimera Sciences has a P/B Ratio of 4.15. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsThe asset beating inflation by 4x"Trump Loophole" Beats Inflation? Inflation has been out of control for years. Forcing you to work longer and harder for more money that is worth less. By using the "Trump Loophole", you can use a special retirement account to buy gold — and other precious metals — without taxes or penalties.That's why we have released our Free Precious Metals Investment Guide that explains all the details About Alimera Sciences Stock (NASDAQ:ALIM)Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.Read More ALIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALIM Stock News HeadlinesApril 30, 2024 | finance.yahoo.comAlimera Sciences to Report First Quarter 2024 Financial Results on May 14, 2024, and Provide Corporate UpdateApril 30, 2024 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Stock Price Passes Above 200-Day Moving Average of $3.64May 5, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 30, 2024 | americanbankingnews.comStockNews.com Downgrades Alimera Sciences (NASDAQ:ALIM) to HoldApril 3, 2024 | finance.yahoo.comLuckie & Company Acquires Marbury Creative GroupApril 3, 2024 | bizjournals.comLuckie & Co. acquires Atlanta marketing agencyMarch 26, 2024 | finance.yahoo.comOcular Inflammation Treatment Market InsightAce Exclusive Report 2024-2031March 20, 2024 | finance.yahoo.comAlimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” March 19, 2024 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 19, 2024 | finance.yahoo.comAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 19, 2024 | globenewswire.comAlimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina NetworkMarch 18, 2024 | msn.comMizuho downgrades Amylyx to Neutral after ALS trial setbackMarch 10, 2024 | realmoney.thestreet.comAlimera Sciences price target raised by $1 at H.C. Wainwright, here's whyMarch 9, 2024 | seekingalpha.comAlimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alimera Sciences Amid Strong Financial Performance and Promising Clinical TrialsMarch 8, 2024 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call TranscriptMarch 8, 2024 | finance.yahoo.comQ4 2023 Alimera Sciences Inc Earnings CallMarch 7, 2024 | investorplace.comALIM Stock Earnings: Alimera Sciences Beats Revenue for Q4 2023March 7, 2024 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsMarch 7, 2024 | globenewswire.comAlimera Sciences Reports Fourth Quarter and Full Year 2023 ResultsMarch 6, 2024 | benzinga.comA Preview Of Alimera Sciences's EarningsMarch 6, 2024 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To ProfitabilityFebruary 29, 2024 | finance.yahoo.comAlimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate UpdateFebruary 10, 2024 | msn.comAlimera Sciences Launches 2024 Equity Inducement PlanFebruary 8, 2024 | finance.yahoo.comThe UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®January 25, 2024 | finance.yahoo.comAlimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years agoSee More Headlines Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/07/2024Today5/04/2024Next Earnings (Confirmed)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees154Year Founded2003Price Target and Rating Average Stock Price Target$7.50 High Stock Price Target$10.00 Low Stock Price Target$5.00 Potential Upside/Downside+105.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($2.16) Trailing P/E RatioN/A Forward P/E Ratio121.67 P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-24.93% Pretax Margin-24.83% Return on Equity-130.90% Return on Assets-10.22% Debt Debt-to-Equity Ratio1.40 Current Ratio2.39 Quick Ratio2.31 Sales & Book Value Annual Sales$80.75 million Price / Sales2.37 Cash FlowN/A Price / Cash FlowN/A Book Value$0.88 per share Price / Book4.15Miscellaneous Outstanding Shares52,380,000Free Float35,929,000Market Cap$191.19 million OptionableOptionable Beta1.20 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Richard S. Eiswirth Jr. (Age 56)CEO & Director Comp: $597.87kMr. David R. Holland (Age 60)Co-Founder, Chief Marketing Officer and Senior VP of Corporate Communications & Managed Markets Comp: $413.5kDr. Philip Ashman Ph.D. (Age 59)President of International Operations Comp: $389.86kMr. Todd Michael Wood (Age 54)President of U.S. Operations Mr. Elliot Maltz CPA (Age 39)CFO & Treasurer Mr. Jason WernerChief Operating OfficerChristopher S. VisickVP, General Counsel & SecretaryDr. David Dyer M.D.Chief Retina SpecialistMore ExecutivesKey CompetitorsLifecore BiomedicalNASDAQ:LFCRTelomir PharmaceuticalsNASDAQ:TELOAtossa TherapeuticsNASDAQ:ATOSEliem TherapeuticsNASDAQ:ELYMGeneration BioNASDAQ:GBIOView All CompetitorsInsiders & InstitutionsFifth Lane Capital LPBought 21,238 shares on 5/2/2024Ownership: 0.041%Stonepine Capital Management LLCBought 15,773 shares on 2/13/2024Ownership: 7.630%AIGH Capital Management LLCSold 146,504 shares on 2/12/2024Ownership: 4.247%Worth Venture Partners LLCSold 37,067 shares on 2/9/2024Ownership: 1.062%Caligan Partners LpBought 579,000 shares on 9/14/2023Total: $1.96 M ($3.39/share)View All Insider TransactionsView All Institutional Transactions ALIM Stock Analysis - Frequently Asked Questions Should I buy or sell Alimera Sciences stock right now? 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks. What is Alimera Sciences' stock price target for 2024? 3 brokers have issued twelve-month price objectives for Alimera Sciences' stock. Their ALIM share price targets range from $5.00 to $10.00. On average, they predict the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 105.5% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts. How have ALIM shares performed in 2024? Alimera Sciences' stock was trading at $4.32 at the beginning of 2024. Since then, ALIM stock has decreased by 15.5% and is now trading at $3.65. View the best growth stocks for 2024 here. Are investors shorting Alimera Sciences? Alimera Sciences saw a increase in short interest in March. As of March 31st, there was short interest totaling 108,800 shares, an increase of 26.8% from the March 15th total of 85,800 shares. Based on an average trading volume of 81,900 shares, the days-to-cover ratio is presently 1.3 days. View Alimera Sciences' Short Interest. When is Alimera Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our ALIM earnings forecast. How can I listen to Alimera Sciences' earnings call? Alimera Sciences will be holding an earnings conference call on Tuesday, May 14th at 9:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "9720210". How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) released its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.09. The biopharmaceutical company earned $26.31 million during the quarter, compared to analyst estimates of $25.10 million. Alimera Sciences had a negative net margin of 24.93% and a negative trailing twelve-month return on equity of 130.90%. During the same quarter in the prior year, the business posted ($0.54) earnings per share. When did Alimera Sciences' stock split? Alimera Sciences's stock reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What guidance has Alimera Sciences issued on next quarter's earnings? Alimera Sciences updated its FY 2024 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $105.0 million-, compared to the consensus revenue estimate of $103.7 million. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB). Who are Alimera Sciences' major shareholders? Alimera Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Fifth Lane Capital LP (0.04%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Adam Morgan, Alto Investors Lp Palo, Caligan Partners Lp, James R Largent, John Philip Jones, Richard S Eiswirth Jr and Stanley Morgan. View institutional ownership trends. How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALIM) was last updated on 5/5/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyAutomatic Income (from home)Awesomely, LLCThe asset beating inflation by 4xColonial MetalsCould Your Accounts Be Frozen?Allegiance GoldThe only AI company you should be looking atBehind the MarketsHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceUrgent Nvidia WarningAltimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
